Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021

Rhea-AI Summary

Brickell Biotech, Inc. (Nasdaq: BBI) announced it will report its financial results for Q2 2021, ending June 30, during a conference call on August 12, 2021, at 4:30 PM ET. The call will provide insights into recent corporate highlights and developments. Investors can access the call via phone or through a live webcast on Brickell's website. The company focuses on innovative therapeutics for skin diseases, with a particular emphasis on its lead product, sofpironium bromide, aimed at treating hyperhidrosis.

Positive

• Upcoming Q2 2021 financial results expected to provide insights into business performance.
• Focus on innovative treatment for hyperhidrosis could address unmet patient needs.

Negative

• None.

BOULDER, Colo., July 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced today that it will report its financial results for the second quarter, ended June 30, 2021. Brickell’s management will host a conference call and webcast at 4:30 pm ET on Thursday, August 12^th to discuss the financial results and recent corporate highlights.

To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13720599. To access the live webcast, please go to the Investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis^®, Taltz^®, Gemzar^®, Prozac^®, Cymbalta^® and Juvederm^®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs. For more information, visit https://www.brickellbio.com.

Brickell Investor Contact:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com

FAQ

When will Brickell Biotech report its Q2 2021 financial results?

Brickell Biotech will report its Q2 2021 financial results on August 12, 2021, at 4:30 PM ET.

What is the significance of sofpironium bromide for Brickell Biotech?

Sofpironium bromide is Brickell's lead asset targeting hyperhidrosis, which represents a significant focus for the company.

How can investors access the Brickell Biotech conference call?

Investors can access the call by dialing 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. with the conference ID 13720599, or through a live webcast on Brickell's website.

What are Brickell Biotech's main areas of focus?

Brickell focuses on developing innovative prescription therapeutics for debilitating skin diseases.